Both in Biotechnology
Acumen Pharmaceuticals vs Estrella Immunopharma
Over the past year ABOS returned −89.5% and ESLA returned −84.0%; their daily moves had a correlation of 0.09.
ABOS −89.5% ESLA −84.0%Growth of $1, one year, split-adjusted
| Metric | ABOS | ESLA |
|---|---|---|
| Price | $0.2138 | $0.4101 |
| Market cap | $15.5M | $17.8M |
| Today | −1.16% | −7.53% |
| 1 month | −89.8% | −2.2% |
| 6 months | −91.3% | −67.7% |
| Year to date | −89.9% | −73.7% |
| 1 year | −89.0% | −82.1% |
| Revenue growth (YoY) | — | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | $52.3M | $146.7K |
| Dividend yield | — | — |
| Volatility (60d) | 492.8% | 201.7% |
| Short % of float | 7.6% | 4.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).